Why isn’t medicine one size fits all?
Our scientists break down precision medicine and the role of genomics research.
Genomics
We’re leading one of the largest genomics research efforts in the world to discover and deliver the right medicines for the right patient at the right time.
Unlocking the power of genomic data
Genomics is swiftly moving to the forefront of medicine and helping transform health care by making it more personalized and proactive.
With access to more than 1 million genomes, AbbVie scientists are leading one of the world’s largest genomics research efforts, using real-world data, single-cell transcriptomics, epigenetics and other cutting-edge technologies to make revolutionary advancements that wouldn't have been possible only a few years ago.
Through building a greater understanding of disease biology and how medicine works at the individual level, we’re working to develop and deliver new and more tailored medicines for the right patient at the right time.
In 2016, AbbVie centralized all genetic and genomic work within the company and formed AbbVie’s Genomics Research Center. The center includes six specialized teams:
Accelerating drug discovery and development
Genomics is the study of our DNA, which acts as a personal health blueprint for all of us.
Today, the experts at AbbVie’s Genomics Research Center are analyzing and interpreting millions of ‘blueprints’ to determine what causes some of the world’s most challenging diseases and learn why people have unique risk factors, respond differently to certain treatments and more.
Breaking down massive amounts of human data to unearth solutions that work on the individual level, we’re working to improve disease prediction and produce precision medicines, more efficiently, to deliver them to patients faster.
Related content
Topics
Pioneering scientific breakthroughs with human data
We’re focused on finding connections between our genes and health to better understand and treat disease. Our interests include:
- Utilizing innovative gene editing systems as a bridge between genomics and biology
- Leveraging computational biology enabling multi-omics data integration, machine learning and human biology characterization to drive innovation
- Leveraging rare diseases to discover and/or validate targets ultimately to help us design more individualized medicines for patients
- Providing genetic evidence to repurpose some of our existing medicines into new indications
- Implementing induced pluripotent stem cells (iPSCs) with gene editing and genomics
- Applying cutting-edge platforms integrated with automated wetlab and standardized analysis pipeline for high-throughput multi-omic data generation
- Using artificial intelligence (AI)/machine learning (ML) and predictive modeling for a variety of analyses for target prioritization, extracting knowledge from multi-omics data, imaging and others
- Using human genetic data to accelerate R&D and reduce failure rates
Interested in a fast-paced career in science?
Help us create the future of medicine.
Popular pages
External links
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
Copyright © 2024 AbbVie Inc. North Chicago, Illinois, U.S.A.
